Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc publishes the 2020 Annual Report
Stockholm, March 31, 2021 – Intervacc AB (publ) announces that the company’s 2020 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the...DNA investigation highlights the ’unbridled globetrotting’ of the Strangles pathogen in horses
Stockholm, March 9, 2021 – In the largest ever study of its kind into an equine pathogen, which was published today in the journal ’Microbial Genomics’, scientists in 18 countries used the latest DNA sequencing techniques to track the bacteria...Year-end report January – December 2020
The period in summary January 1 – December 31, 2020 Our marketing authorization application for Strangvac® was submitted to the European Medicines Agency, EMA, at the end of February 2020. After having received the Day 120 questions from EMA we have strengthened the...Intervacc Announces Submission of Responses to EMA Day 120 Questions
Stockholm, January 12, 2021 – Intervacc AB (publ) announces that the responses to the Day 120 questions regarding the Company’s Marketing Authorization Application (MAA) for Strangvac® has been submitted today to the European Medicines Agency (EMA). Intervacc is...Intervacc appoints Emma Hartman as Global Product Manager for Strangvac
Stockholm, November 25, 2020 – The animal health group Intervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease...Nyhetstjänster
